Jupiter, FL – Uniquity Bio has announced the appointment of Matthew Hartzell as Chief Financial Officer. About Uniquity Bio: Uniquity Bio is a clinical-stage biopharmaceutical company focused on developing innovative medicines for immune-mediated diseases, with a particular emphasis on immunology and inflammation. Built by a leadership team with decades of experience in global pharma, biotech, and research, the company combines scientific rigor with operational agility to deliver powerful solutions quickly to patients who have limited or no available treatment options. As a Blackstone Life Sciences portfolio company, Uniquity Bio benefits from committed capital and deep development expertise to support a dynamic pipeline of high-potential medicines and to create value for patients, partners, and investors. The companys lead asset is solrikitug, a highly potent monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), which was in-licensed from Merck & Co., Inc. and is being advanced in Phase 2 clinical trials for chronic obstructive pulmonary disease (COPD), asthma, and eosinophilic esophagitis (EoE), indications where best-in-class efficacy and new options are urgently needed. Guided by the principle Science leads us; patients inspire us, Uniquity Bio is actively building and executing a trusted clinical development strategy to deliver meaningful, best-in-class products to patients and industry partners in the field of immunology and inflammation.

For more information visit: https://www.uniquity.com/

Uniquity Bio
825 Center St
Jupiter, FL 33458
Phone: 484-267-2500
LinkedIn: https://www.linkedin.com/company/uniquity/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved